Member Info for Chris0123

Roll forward 4 years to an LSE exchange toward the final stages of CAR T clinical trials:-

- RNA announcement "99% (99 out of 100) of patients made a complete recovery during latter stage trials"

- Yeah but what about the one person who sadly died? Did he die as a result of the trial which will impact the share price dramatically?

- No he was hit by a bus and it won't affect the SP

- How do you know?

-I read the autopsy report.

- Could it have been someone else's autopsy report?

- No it was definitely the trial patients, I researched it

- Did it specifically mention bus or is that your interpretation?

- No it stated bus

- Can you send me the link

- Go research it yourself, I'm not your secretary

- Alright, I have seen the link to the autopsy report, it did say bus.

- At last !

- I note he died after a Hemo Car T treatment, the same day in fact

- And your point is?

- He could have been affected by the Hemo treatment that day, lost his concentration whilst running for the No. 47 heading Downtown and that means there is a link to Hemo and his untimely death

- The autopsy report did not say that

- There is usually a follow up report in 30 days - so mid October, the shares will plummet and the compensation claim will be massive. VS will need to fund raise, there will be dilution

- why don't you just FO !!

GLA

-

With VS's pitch to investors taking place on Monday 18th on the subject of CBR it would lead me toward thinking that he will have to go further than our current understanding as regards progress achieved in the lab, if he is to be successful. Therefore, it follows that if he is giving a deeper insight to "potential" investors then we, as real investors, might see something in an RNS which updates us on progress. What are the odds do you think of seeing something before Friday close. GLA PS one2one are you using artificial intelligence to paragraph your posts or is that just you.

I happened to pick up the documentary on the Branch Davidians led by the infamous David Koresh screened over the last 2 weekends. It was reported within the documentary that he obtained funding from followers giving over their money and assets on joining the sect. As I was leaving the room, my wife referenced me giving "our" money away to a "cu*t"., sarcastically referring to my Hemogenyx investment. It was at this point that I had to check myself as I passed through the doorway unsure of what last word I had heard as she was not normally prone to use of that sort of language. She definitely said "cult" but, I admit, at times I have had to persuade her with every sinew that I am not Waco, sorry that's "wacko" and that this IS a very sound investment.

I believe that even more now and I think that we are reaching rich pastures of good news. I sincerely hope we get some positives soon and I hope everyone can keep the faith so to speak. C'mon David, I mean Vlad, make our day! GLA

Monday will be interesting. If they were only to tell us on the back of this patent publication that lab work with CBR was progressing well - boy what an endorsement that would be. Good luck to those hanging onto their shares through the weekend. GLA

Looks like a good buy this morning Dhub - well done. At the risk of sounding slapstick and a bit "Carry On" I know you already had a big holding, so fair play to you. For every 0.0001p shift it was probably about £11k to you and you have been positive, like a number of others most of the time. It is still early days and we still need RNS positive news, without it we will probably roll back but good to see how much this even this hidden new can generate.

I think the Pharma paid scientific community will be derelict in their duty not to be aware of this patent publication - it could cost them dearly so they need to know anything and everything that goes on and even before today there must have been a watching brief. Competitors are not going to extol the potential virtues of CBR publicly, if it's big they will want in and in at a lower price than if they bulled it up openly. Great day on a mere publication - enjoy the sun all.

If Hemo have a potential cure for multiple conditions you would think that the big Pharma would be sticking their noses in to ensure they are not infringed in any way, the whole basis for publication of any patent application. Their interest, even negative, would get us some attention. Be good for them to show an interest in the claims, given how extensive they are. GLA

Hi one2one, I like to tune into LSE (albeit less so now) but by God, you are so divisive and insidious to the point where you insult a multitude of investors with your poorly constructed rants and unaccompanied links just thrown out without comment. I and many have hard earned cash in this stock and ultimately I will leave it to Hemo to reward me handsomely or sh*ft me royally. I don't need you delighting in spreading distrust and negativity. AIMO

Hi Stu you mentioned the word "researched alternative" in one of your posts. Given that you are expecting news soon but put a proposition forward that suggests a timeline not before year end for FDA / CH news, I would be interested to know what "research" leads you to the conclusion that you are expecting news and an uplift presumably on CBR or CDX.

Given the 3, CDX CART T and CBR, FDA response on the CH would likely be higher than the other two given the elapsed time form CH. Why makes you believe different. Be good to get an insight on that. GLA

Apologies that was Gilead not Eli Lily - no offence to whoever.

Eli Lily have just had a CAR T therapy clinical hold of their own lifted by the FDA (Source: Fierce Pharma). It was only put on CH in June as a result of a trial patient death. There is a lot more detail to this but it is perhaps just an illustration that the FDA can move quickly given the information they need to reverse a decision. Hemo, fortunately, have not had a patient death and we have just one issue raised which has created the CH. I think that should give us confidence that if the FDA get what they need from Hemo, they can act pretty quickly their end if the Eli Lily timescales are anything to go by. GLA

I think you have had enough beer Micky from reading that post. GLA you and all.

Thanks for your expansion on this topic Jez & Digitt - comfortable whatever it takes. The most important thing for all of us is that Hemogenyx fully understand and get it right or ensure WuXi do. At least the FDA did not detail a litany of issues requiring an entire re-examination of the submission. Good to know we are 95% (or thereabouts) closer to clinical trial.

All the best all. PS If the traders can leave the end of day SP at 1.7 p that's be a nice finish today - thanks in anticipation.

I did some reading around the production of lentivirus and noted a number of references to timescales of 3-4 weeks by various producers. I appreciate not all are the same and there may be checking processes thereafter but in my opinion I do not think that we are months and months away from re-engagement with the FDA re approval. Once this issue is addressed, likewise it should not take the FDA too long to validate that the matter has been addressed. Just an opinion from what I can glean, hopefully not too wide of the mark. 3-4 weeks will fly in. GLA

As frustrating as it is sometimes, I am not sure a 1.7m net sell off of shares today constitutes a big expression of market dissatisfaction. GLA

Perhaps one of these days Tuan6 will be able to take on the character of "Loadsamaney" rather than Harry Enfield's Stavros.

With this share there are many, me included, who believe Hemogenyx will make loads of money in the process of saving lives. GLA

Mickyc333 - what has changed? I recall your comment after the AGM that he (Dr Sandler) has answered your questions and you seemed more than content. There were some strong statements regarding going into clinical trials - would it not be best to listen to what has been directly stated than perhaps try to interpret body language alone. GLA

One for Pumpky, the jockey on this horse has got a real handful coming into the straight, it has to be released at any moment. GLA

Company Secretary and Financial Controller are both important enough positions. May be he is staying as Financial Controller in an expanded role following new partnership and a sizeable injection of cash to oversee perhaps. Would seem odd that Hulver's find does not expand on the FC element of his role. Incidentally, Andrew Wright bought 1.28 m shares in May 22 at almost the current price. I think a seller if he is moving on completely and a holder if he retains the FC role. Time will tell. GLA

Hopefully not an FDA letter leak. It's a real conundrum this share. Stay positive. Best of luck all.

Alert over ...now corrected.